Procter & Gamble Health Future Growth
Future criteria checks 1/6
Procter & Gamble Health is forecast to grow earnings and revenue by 11.3% and 8.8% per annum respectively while EPS is expected to grow by 11.3% per annum.
Key information
11.3%
Earnings growth rate
11.3%
EPS growth rate
Pharmaceuticals earnings growth | 17.6% |
Revenue growth rate | 8.8% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 06 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Here's Why Procter & Gamble Health Limited's (NSE:PGHL) CEO Compensation Is The Least Of Shareholders' Concerns
Nov 29Procter & Gamble Health (NSE:PGHL) Is Due To Pay A Dividend Of ₹60.00
Nov 15Risks To Shareholder Returns Are Elevated At These Prices For Procter & Gamble Health Limited (NSE:PGHL)
Nov 05Procter & Gamble Health (NSE:PGHL) Has Announced A Dividend Of ₹60.00
Sep 28Procter & Gamble Health (NSE:PGHL) Has Announced A Dividend Of ₹60.00
Aug 27Earnings Not Telling The Story For Procter & Gamble Health Limited (NSE:PGHL)
Jun 08Weak Statutory Earnings May Not Tell The Whole Story For Procter & Gamble Health (NSE:PGHL)
Feb 14Procter & Gamble Health (NSE:PGHL) Has Announced That It Will Be Increasing Its Dividend To ₹50.00
Sep 29Procter & Gamble Health's (NSE:PGHL) Shareholders Will Receive A Bigger Dividend Than Last Year
Sep 10Procter & Gamble Health's (NSE:PGHL) Shareholders Will Receive A Bigger Dividend Than Last Year
Aug 27A Look At The Fair Value Of Procter & Gamble Health Limited (NSE:PGHL)
Mar 30We Think The Compensation For Procter & Gamble Health Limited's (NSE:PGHL) CEO Looks About Right
Nov 17Procter & Gamble Health (NSE:PGHL) Has Announced That Its Dividend Will Be Reduced To ₹11.50
Oct 23Procter & Gamble Health's (NSE:PGHL) Dividend Will Be Reduced To ₹11.50
Oct 09Procter & Gamble Health's (NSE:PGHL) Problems Go Beyond Weak Profit
Feb 16Do Procter & Gamble Health's (NSE:PGHL) Earnings Warrant Your Attention?
Oct 04Here's Why I Think Procter & Gamble Health (NSE:PGHL) Is An Interesting Stock
May 10Would Procter & Gamble Health Limited (NSE:PGHL) Be Valuable To Income Investors?
Mar 23Is Weakness In Procter & Gamble Health Limited (NSE:PGHL) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
Mar 02Should You Be Adding Procter & Gamble Health (NSE:PGHL) To Your Watchlist Today?
Jan 31Here's What Procter & Gamble Health Limited's (NSE:PGHL) Shareholder Ownership Structure Looks Like
Jan 10Is Procter & Gamble Health Limited (NSE:PGHL) An Attractive Dividend Stock?
Dec 19Is Procter & Gamble Health Limited's (NSE:PGHL) Latest Stock Performance A Reflection Of Its Financial Health?
Dec 01Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
6/30/2026 | 13,536 | 2,650 | N/A | N/A | 1 |
6/30/2025 | 12,546 | 2,376 | N/A | N/A | 1 |
9/30/2024 | 11,597 | 2,177 | N/A | N/A | N/A |
6/30/2024 | 11,513 | 2,010 | 2,066 | 2,283 | N/A |
3/31/2024 | 11,686 | 2,140 | N/A | N/A | N/A |
12/31/2023 | 12,370 | 2,267 | 1,527 | 1,740 | N/A |
9/30/2023 | 12,370 | 2,314 | N/A | N/A | N/A |
6/30/2023 | 12,296 | 2,295 | 1,935 | 2,360 | N/A |
3/31/2023 | 12,243 | 2,408 | N/A | N/A | N/A |
12/31/2022 | 11,712 | 2,328 | 2,718 | 3,349 | N/A |
9/30/2022 | 11,392 | 2,008 | N/A | N/A | N/A |
6/30/2022 | 11,144 | 1,925 | 1,316 | 1,695 | N/A |
3/31/2022 | 11,039 | 1,853 | N/A | N/A | N/A |
12/31/2021 | 10,552 | 1,499 | 816 | 1,157 | N/A |
9/30/2021 | 10,176 | 1,729 | N/A | N/A | N/A |
6/30/2021 | 10,087 | 1,768 | 1,947 | 2,473 | N/A |
3/31/2021 | 9,219 | 1,884 | N/A | N/A | N/A |
12/31/2020 | 9,308 | 2,191 | N/A | N/A | N/A |
9/30/2020 | 9,274 | 1,894 | N/A | N/A | N/A |
6/30/2020 | 8,886 | 1,659 | 1,414 | 1,569 | N/A |
3/31/2020 | 9,237 | 1,645 | N/A | N/A | N/A |
12/31/2019 | 9,266 | 1,588 | 1,512 | 1,619 | N/A |
9/30/2019 | 8,942 | 1,340 | N/A | N/A | N/A |
6/30/2019 | 8,952 | 1,394 | N/A | N/A | N/A |
3/31/2019 | 8,819 | 1,281 | N/A | N/A | N/A |
12/31/2018 | 8,490 | 1,017 | -1,571 | -1,304 | N/A |
9/30/2018 | 12,290 | 1,349 | N/A | N/A | N/A |
6/30/2018 | 12,087 | 1,140 | N/A | N/A | N/A |
3/31/2018 | 11,762 | 1,018 | N/A | N/A | N/A |
12/31/2017 | 6,981 | 610 | N/A | 537 | N/A |
9/30/2017 | 10,523 | 828 | N/A | N/A | N/A |
6/30/2017 | 10,088 | 797 | N/A | N/A | N/A |
3/31/2017 | 10,177 | 823 | N/A | N/A | N/A |
12/31/2016 | 9,926 | 791 | N/A | 1,070 | N/A |
9/30/2016 | 9,810 | 723 | N/A | N/A | N/A |
6/30/2016 | 9,681 | 572 | N/A | N/A | N/A |
3/31/2016 | 9,589 | 562 | N/A | N/A | N/A |
12/31/2015 | 9,383 | 536 | N/A | 835 | N/A |
9/30/2015 | 9,148 | 401 | N/A | N/A | N/A |
6/30/2015 | 8,798 | 451 | N/A | N/A | N/A |
3/31/2015 | 8,712 | 493 | N/A | N/A | N/A |
12/31/2014 | 8,662 | 432 | N/A | 50 | N/A |
9/30/2014 | 8,544 | 516 | N/A | N/A | N/A |
6/30/2014 | 8,409 | 498 | N/A | N/A | N/A |
3/31/2014 | 8,082 | 455 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PGHL's forecast earnings growth (11.3% per year) is above the savings rate (6.7%).
Earnings vs Market: PGHL's earnings (11.3% per year) are forecast to grow slower than the Indian market (18.1% per year).
High Growth Earnings: PGHL's earnings are forecast to grow, but not significantly.
Revenue vs Market: PGHL's revenue (8.8% per year) is forecast to grow slower than the Indian market (10.6% per year).
High Growth Revenue: PGHL's revenue (8.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PGHL's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/03 20:58 |
End of Day Share Price | 2025/01/03 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Procter & Gamble Health Limited is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Rohit Bhat | Batlivala & Karani Securities India Pvt. Ltd. |
Ranjit Kapadia | Centrum Broking Limited |
Anil Burra | FirstCall Research |